Metformin exposure and disseminated disease in patients with colorectal cancer

Cancer Epidemiology

Volumn 38, Issue 1, 2014, Pages 79-84

  Spillane, Susan ^a   Bennett, Kathleen ^a   Sharp, Linda ^b   Barron, Thomas I ^a  

^a ST JAMES S HOSPITAL   (Ireland)

^b NATIONAL CANCER REGISTRY IRELAND   (Ireland)

Author keywords

Biguanides; Colorectal neoplasms; Diabetes mellitus; Lymph nodes; Metformin; Neoplasm metastasis; Pharmacoepidemiology; Type 2

Indexed keywords

BIGUANIDES; COLORECTAL NEOPLASMS; DIABETES MELLITUS; LYMPH NODES; METFORMIN; NEOPLASM METASTASIS; PHARMACOEPIDEMIOLOGY; TYPE 2;

AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; IRELAND; LOGISTIC MODELS; LYMPHATIC METASTASIS; MALE; METFORMIN; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS;

EID: 84894228437     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2013.12.003     Document Type: Article

References (40)

1. Zhang P., Li H., Tan X., Chen L., Wang S. Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol 2013, 37(June (3)):207-218.
2. Zhang Z.J., Zheng Z.J., Kan H., Song Y., Cui W., Zhao G., et al. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care 2011, 34(October (10)):2323-2328.
3. Garrett C.R., Hassabo H.M., Bhadkamkar N.A., Wen S., Baladandayuthapani V., Kee B.K., et al. Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. Br J Cancer 2012, 106(April (8)):1374-1378.
4. Lee J.H., Kim T.I., Jeon S.M., Hong S.P., Cheon J.H., Kim W.H. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int J Cancer 2012, 131(August (3)):752-759.
5. Spillane S.C., Bennett K., Sharp L., Barron T.I. A cohort study of metformin exposure and survival in patients with stage I-III colorectal cancer. Cancer Epidemiol Biomarkers Prev 2013, (June). [in press]. 10.1158/1055-9965.EPI-13-0347.
6. Sarfstein R., Friedman Y., Attias-Geva Z., Fishman A., Bruchim I., Werner H. Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners. PLoS ONE 2013, 8(4):e61537. 10.1371/journal.pone.0061537.
7. Wu B., Li S., Sheng L., Zhu J., Gu L., Shen H., et al. Metformin inhibits the development and metastasis of ovarian cancer. Oncol Rep 2012, (June). [in press]. 10.3892/or.2012.1890.
8. Tan B.K., Adya R., Chen J., Lehnert H., Sant Cassia L.J., Randeva H.S. Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells. J Clin Endocrinol Metab 2011, 96(3):808-816.
9. Rattan R., Graham R.P., Maguire J.L., Giri S., Shridhar V. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia 2011, 13(May (5)):483-491.
10. Vazquez-Martin A., Oliveras-Ferraros C., Cufi S., Del Barco S., Martin-Castillo B., Lopez-Bonet E., et al. The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells. Oncol Rep 2011, 25(January (1)):135-140.
11. Hwang Y.P., Jeong H.G. Metformin blocks migration and invasion of tumour cells by inhibition of matrix metalloproteinase-9 activation through a calcium and protein kinase C(alpha)-dependent pathway: phorbol-12-myristate-13-acetate-induced/extracellular signal-regulated kinase/activator protein-1. Br J Pharmacol 2010, 160(5):1195-1211.
12. Bao B., Wang Z., Ali S., Ahmad A., Azmi A.S., Sarkar S.H., et al. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res (Phila) 2012, 5(March (3)):355-364.
13. Liao H., Zhou Q., Gu Y., Duan T., Feng Y. Luteinizing hormone facilitates angiogenesis in ovarian epithelial tumor cells and metformin inhibits the effect through the mTOR signaling pathway. Oncol Rep 2012, 27(June (6)):1873-1878.
14. Rattan R., Ali Fehmi R., Munkarah A. Metformin: an emerging new therapeutic option for targeting cancer stem cells and metastasis. J Oncol 2012, 928127. [in press]. 10.1155/2012/928127.
15. Hsieh A.C., Liu Y., Edlind M.P., Ingolia N.T., Janes M.R., Sher A., et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 2012, 485(May (7396)):55-61.
16. Glasgow S.C., Bleier J.I., Burgart L.J., Finne C.O., Lowry A.C. Meta-analysis of histopathological features of primary colorectal cancers that predict lymph node metastases. J Gastrointest Surg 2012, 16(May (5)):1019-1028.
17. Burke P. Primary care reimbursement service; statistical analysis of claims and payments 2010 2013, Health Service Executive, Available from: http://www.hse.ie/eng/staff/PCRS/PCRS_Publications/claimsandpayments2010.pdf.
18. Greene F., Page D.L., Fleming I.D., et al. AJCC cancer staging manual 2002, Springer, New York. 6th ed.
19. World Health Organisation International classification of diseases (ICD): ICD-10 online 2013, Available at: http://www.who.int/classifications/icd/en/ [accessed 13.11.13].
20. WHO Collaborating Centre for Drug Statistics Methodology ATC classification index with DDDs. Oslo 2012, Available from: http://www.whocc.no/atc_ddd_index [accessed 07.07.13].
21. Peterson A.M., Nau D.P., Cramer J.A., Benner J., Gwadry-Sridhar F., Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007, 10(January-February (1)):3-12.
22. Kourelis T.V., Siegel R.D. Metformin and cancer: new applications for an old drug. Med Oncol 2012, 29(June (2)):1314-1327.
23. Yang X.L., Ma R.C., So W.Y., Kong A.P., Xu G., Chan J.C. Addressing different biases in analysing drug use on cancer risk in diabetes in non-clinical trial settings - what, why and how?. Diabetes Obes Metab 2012, 14(July (7)):579-585.
24. Kelly A., Teljeur C. The national deprivation index for health & health services research 2007, Small Area Health Research Unit, Sahru Technical Report, Trinity College Dublin.
25. Rothwell P.M., Wilson M., Price J.F., Belch J.F., Meade T.W., Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012, 379(April (9826)):1591-1601.
26. Schneeweiss S., Seeger J.D., Maclure M., Wang P.S., Avorn J., Glynn R.J. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001, 154(November (9)):854-864.
27. Shrier I., Platt R. Reducing bias through directed acyclic graphs. BMC Med Res Methodol 2008, 8(1):70.
28. Textor J., Hardt J., Knüppel S., DAGitty A graphical tool for analyzing causal diagrams. Epidemiology 2011, 22(5):745. 10.1097/EDE.0b013e318225c2be.
29. Maldonado G., Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol 1993, 138(December (11)):923-936.
30. Vansteelandt S., Bekaert M., Claeskens G. On model selection and model misspecification in causal inference. Stat Methods Med Res 2012, 21(February (1)):7-30.
31. Feng Y.H., Wu C.L., Shiau A.L., Lee J.C., Chang J.G., Lu P.J., et al. MicroRNA-21-mediated regulation of Sprouty2 protein expression enhances the cytotoxic effect of 5-fluorouracil and metformin in colon cancer cells. Int J Mol Med 2012, 29(May (5)):920-926.
32. Pollak M.N. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov 2012, 2(September (9)):778-790.
33. Zhang C., Hao L., Wang L., Xiao Y., Ge H., Zhu Z., et al. Elevated IGFIR expression regulating VEGF and VEGF-C predicts lymph node metastasis in human colorectal cancer. BMC Cancer 2010, 10:184.
34. Sridhar S.S., Goodwin P.J. Insulin-insulin-like growth factor axis and colon cancer. J Clin Oncol 2009, 27(January (2)):165-167.
35. Hitron A., Adams V., Talbert J., Steinke D. The influence of antidiabetic medications on the development and progression of prostate cancer. Cancer Epidemiol 2012, 36(August (4)):e243-e250.
36. Hou G., Zhang S., Zhang X., Wang P., Hao X., Zhang J. Clinical pathological characteristics and prognostic analysis of 1,013 breast cancer patients with diabetes. Breast Cancer Res Treat 2013, 137(February (3)):807-816.
37. Mazzone P.J., Rai H., Beukemann M., Xu M., Jain A.K., Sasidhar M. The effect of metformin and thiazolidinedione use on lung cancer in diabetics. BMC Cancer 2012, 12(September (1)):410.
38. Lewis J.D., Capra A.M., Achacoso N.S., Ferrara A., Levin T.R., Quesenberry C.P., et al. Medical therapy for diabetes is associated with increased use of lower endoscopy. Pharmacoepidemiol Drug Saf 2007, 16(November (11)):1195-1202.
39. Tabar L., Duffy S.W., Krusemo U.B. Detection method, tumour size and node metastases in breast cancers diagnosed during a trial of breast cancer screening. Eur J Cancer Clin Oncol 1987, 23(July (7)):959-962.
40. Baxter N.N., Virnig D.J., Rothenberger D.A., Morris A.M., Jessurun J., Virnig B.A. Lymph node evaluation in colorectal cancer patients: a population-based study. J Natl Cancer Inst 2005, 97(February (3)):219-225.